Manila Times Business
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone” or the "Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones. The Company’s full set of unaudited condensed interim consolidated financial statements for
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Sweden health agency tells parents to put down phones
Just now
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
Just now
Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 5.42 Million Tokens, and Total Crypto and Total Cash Holdings of $11.6 Billion
Just now
NATURE'S MIRACLE HOLDING INC. SECURES $566,000 CONVERTIBLE PREFERRED STOCK FINANCING
Just now